Spruce Biosciences
Most recent annual filing: 2026-03-09
- TA-ERT tralesinidase alfa BLA filing4Q 2026TA-ERT tralesinidase alfa BLA filing, 4Q 2026, major
- TA-ERT tralesinidase alfa AdCom1H 2027TA-ERT tralesinidase alfa AdCom, 1H 2027, thesis-defining
- TA-ERT tralesinidase alfa PDUFA date1H 2027TA-ERT tralesinidase alfa PDUFA date, 1H 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
SPR202
Discontinued (1)
- tildacerfont — Major Depressive Disorder · serious adverse event — significant elevation of liver enzymes in a patient
Biotech Distilled coverage (4)
- 2026-08-24 UPDATE: Spruce Biosciences (SPRB) - The Factory Signed Off 🔒 Paid
- 2026-08-13 UPDATE: Spruce Biosciences (SPRB) - The Patients Just Bought the Stock 🔒 Paid
- 2026-07-28 UPDATE: Spruce Biosciences (SPRB) - They Hired the Man Who Launched Brineura
- 2026-05-08 Spruce Biosciences (SPRB) - Scientific Deep Dive for Tralesinidase and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.